Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Arthritis Research and Therapy Année : 2014

Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis

Résumé

Introduction: Regulatory T (Treg) cells play a crucial role in preventing autoimmune diseases and are an ideal target for the development of therapies designed to suppress inflammation in an antigen-specific manner. Type 1 regulatory T (Tr1) cells are defined by their capacity to produce high levels of interleukin 10 (IL-10), which contributes to their ability to suppress pathological immune responses in several settings. The aim of this study was to evaluate the therapeutic potential of collagen type II–specific Tr1 (Col-Treg) cells in two models of rheumatoid arthritis (RA) in mice. Methods: Col-Treg clones were isolated and expanded from collagen-specific TCR transgenic mice. Their cytokine secretion profile and phenotype characterization were studied. The therapeutic potential of Col-Treg cells was evaluated after adoptive transfer in collagen-antibody– and collagen-induced arthritis models. The in vivo suppressive mechanism of Col-Treg clones on effector T-cell proliferation was also investigated. Results: Col-Treg clones are characterized by their specific cytokine profile (IL-10highIL-4negIFN-γint) and mediate contact-independent immune suppression. They also share with natural Tregs high expression of GITR, CD39 and granzyme B. A single infusion of Col-Treg cells reduced the incidence and clinical symptoms of arthritis in both preventive and curative settings, with a significant impact on collagen type II antibodies. Importantly, injection of antigen-specific Tr1 cells decreased the proliferation of antigen-specific effector T cells in vivo significantly. Conclusions: Our results demonstrate the therapeutic potential of Col-Treg cells in two models of RA, providing evidence that Col-Treg could be an efficient cell-based therapy for RA patients whose disease is refractory to current treatments.

Domaines

Immunologie
Fichier principal
Vignette du fichier
Version publiée AR4567.pdf (2.22 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

hal-02397296 , version 1 (06-12-2019)

Licence

Paternité - Pas de modifications

Identifiants

Citer

Hélène Asnagli, Delphine Martire, Nathalie Belmonte, Julie Quentin, Hervé Bastian, et al.. Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis. Arthritis Research and Therapy, 2014, 16 (3), ⟨10.1186/ar4567⟩. ⟨hal-02397296⟩
387 Consultations
78 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More